pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Opdivo · news · pharmadog
← back to Opdivo
News mentioning Opdivo
54
stories
Jul 30, 26
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
Jul 28, 26
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
Jul 28, 26
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 23, 26
Scancell to go public after winning reverse merger bid for troubled Neuphoria
fiercebiotech
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 15, 26
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
biopharma dive
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 29, 26
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
biopharma dive
May 11, 26
Biotech layoffs are easing, but is the worst over?
biopharma dive
May 10, 26
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
onclive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 8, 26
Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
onclive
May 8, 26
UT MD Anderson Shares Latest Research Breakthroughs
onclive
May 8, 26
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
onclive
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
May 7, 26
Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
onclive
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 6, 26
Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
onclive
May 6, 26
Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
← prev
page 2 of 2
next →
